Poor Yield of Routine Transthyretin Screening in Patients with Idiopathic Neuropathy

ABSTRACT: Background and objectives: Transthyretin familial amyloid polyneuropathy (TTR-FAP) is caused by a mutation in the transthyretin (TTR) gene. Although classically described as rapidly progressive and life-threatening, recent studies on TTR-FAP show significant genetic and phenotypic heterogeneity depending on geographic localization. In light of new therapeutic advances and their implication for patient management, the aim of our study was to determine the prevalence of TTR-FAP within patients with idiopathic neuropathy in a North American population. Methods: We sequenced the TTR gene in a cohort of patients with idiopathic neuropathy. Genetic screening was performed in 110 patients from two neuromuscular clinics in Montreal, Canada. Results: No variants of unknown significance or pathogenic mutations were detected in the TTR gene. Conclusion: Our study confirms that TTR-FAP is a rare entity in our patient population, and that diagnostic yield of screening all patients with idiopathic neuropathy is very low.

[1]  A. Ducharme,et al.  Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. , 2020, The Canadian journal of cardiology.

[2]  V. Planté-Bordeneuve,et al.  Familial amyloid polyneuropathy , 2019, Journal of the Neurological Sciences.

[3]  M. Gertz,et al.  Advances in the treatment of hereditary transthyretin amyloidosis: A review , 2019, Brain and behavior.

[4]  S. Mellgren,et al.  Screening for Fabry disease and hereditary ATTR amyloidosis in idiopathic small fiber and mixed neuropathy , 2019, Molecular Genetics and Metabolism.

[5]  C. Lacroix,et al.  Upper limb onset of hereditary transthyretin amyloidosis is common in non‐endemic areas , 2018, European journal of neurology.

[6]  S. Mellgren,et al.  Screening for Fabry disease and Hereditary ATTR amyloidosis in idiopathic small‐fiber and mixed neuropathy , 2018, Muscle & nerve.

[7]  L. Santoro,et al.  Autosomal-dominant transthyretin (TTR)-related amyloidosis is not a frequent CMT2 neuropathy “in disguise” , 2018, Orphanet Journal of Rare Diseases.

[8]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[9]  S. Solomon,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[10]  P. Lozeron,et al.  Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy , 2018, Neurology.

[11]  L. Amass,et al.  Estimating the global prevalence of transthyretin familial amyloid polyneuropathy , 2018, Muscle & nerve.

[12]  D. Adams,et al.  Familial amyloid polyneuropathy , 2017, Current opinion in neurology.

[13]  L. Amass,et al.  “Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy , 2016, Journal of the peripheral nervous system : JPNS.

[14]  M. Benson,et al.  A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis , 2015, Neurology and Therapy.

[15]  H. Morita,et al.  Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis , 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[16]  L. Lobato,et al.  Liver transplantation in transthyretin amyloidosis: Issues and challenges , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  Yukio Ando,et al.  Guideline of transthyretin-related hereditary amyloidosis for clinicians , 2013, Orphanet Journal of Rare Diseases.

[18]  M. Maurer,et al.  THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis , 2013, Current medical research and opinion.

[19]  G. Sobue,et al.  Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci , 2008, Journal of Neurology.

[20]  S. Ikeda.  Is familial amyloid polyneuropathy rare? , 2007, Neurology.

[21]  A. Amato,et al.  Transthyretin amyloidosis presenting with multifocal demyelinating mononeuropathies , 2004, Muscle & nerve.

[22]  S. Kito.  [Familial amyloid neuropathy]. , 1978, Nihon rinsho. Japanese journal of clinical medicine.